1Yunfeng Xia1,Youji Li1,Yong Du,et al.Transplant Association of MEGSIN 2093C–2180T haplotype at the 3'untranslated region with disease severity and progression of IgA nephropathy.Nephrol Dial Transplant,2006,21(6):1570-1574.
2Lim CS,Kim SM,Oh YK,et al.Megsin 2093T-2180C haplotype at the 3' untranslated region is associated with poor renal survival in Korean IgA nephropathy patients.Clin Nephrol,2008,70(2):101-109.
3Maixnerová D,Merta M,Reiterova,et al.The influence of two megsin polymorphisms on the progression of IgA nephropathy.Folia Biol Praha,2008,54(2):40-45.
4Mori H,Kaneko Y,Narital,et al.Monocyte chemoattractant protein-1 A-2518G gene polymorphism and renal survival of Japanese patients with immunoglobulin A nephropathy.Clin Exp Nephrol,2005,9(4):297-303.
5Sun Y,Yuan S,Xu X et al.Expression of MCP-1 in renal tissues of patients with IgA nephropathy.Zhong.Nan Da Xue Xue Bao Yi Xue Ban,2009,34(10):1023-1028.
7Suzuki H,Sakuma Y,Kanesaki Y,et al.Close relationship of p las2 minogen activator inhibitor-1 4G/5G polymorphism and p rogression of IgA nephropathy.Clin Nephrol,2004,62(3):173-179.
9Vuong MT.Genetic variation in the transforming growth factor-beta1 gene is associated with susceptibility to IgA nephropathy.Nephrol Dial Transplant,2009,24(10):3061-3067.
10Brezzi B.Primary IgA nephropathy is more severe in TGF-ss1 high secretor patients.J Nephrol,2009,22(6):747-759.
5Teresa YHW, Peter P, Cheuk CS, et al. Association of plasminogen activator inhibitor - 1 4G/4G genotype and type 2 diabetic nephropathy in Chinese patients. Kidney International. 2000,57:632.
6Jeng JR. Association of PAI- 1 gene promoter 4G/5 G polymorphism with plasma PAI - 1 activity in Chinese patients with and without hypertension. Am J Hypertens. 2003,16:290.
7Matsuo S, Lopez - Guisa JM, Cai X, et al. Multifunctionality of PAI - 1 in fibrogenesis: evidence from obstructive nephropathy in PAI - 1 - overexpressing mice. Kidney Int. 2005,67:2221.
8Rerolle JP, Hotly A, Nguyen G, et al. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int. 2000,58 : 1841.
9Suzuki H, Sakuma Y, Kanesaki Y, et al. Close relationship of plasminogen activator inhibitor - 1 4G/5G polymorphism and progression of IgA nephropathy. Clin Nephrol. 2004,62 : 173.
10Angela YMW, Peter P, Fernand MML, et al. Plasminogen activator inhibitor- 1 gene polymorphism 4G/4G genotype and lupus nephritis in Chinese parents. Kidney International. 2001,59 : 1520.
6Feehally J, Farrall M, Boland A, et al. HLA has strongestassociation with IgA nephropathy in genome - wide studies [J]. J Am Soc Nephrol,2010,21:1791 -1797.
7Ding JX, Xu LX, Zhu L, et al. Activity of alpha2,6 - sialyl- transferase and its gene expression in peripheral B lympho- cytes in patients with IgA nephropathy [ J]. Scand J Immu- no1,2009,69 : 174 - 180.
8Glassock RJ. Future prospects for IgA nephropathy. In:Lai KN, editor. Recent advances in IgA nephropathy [ M ]. Sin- gapore : World Scientific. 2009. 403 - 412.
9Mestecky J,TomanaM, Moldoveanu Z, et al. Role of aberrant glycosy - lation of IgA1 molecules in the pathogenesis of IgA nephropathy [ J ]. Kidney Blood Press Res, 2008,31 (1) :29 - 37.
10McGrogan A,Franssen CFM,de Vries CS. The incidence of primary glomeruionephritis worldwide: a systematic review of the literature [ J ]. Nephrol Dial Transplant 2011,26 (2) : 414 - 430.
